The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mature, real world progression-free survival (PFS) and overall survival (OS) milestones in stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) followed by pem+/-bevacizumab(Bev) maintenance.
 
Parva Kiran Bhatt
No Relationships to Disclose
 
Ibtihaj Fughhi
No Relationships to Disclose
 
Sanjib Basu
No Relationships to Disclose
 
Mary J. Fidler
Honoraria - AstraZeneca
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Genentech; Genentech (I); Guardant Health; Guardant Health
Speakers' Bureau - Genentech; Merck
Research Funding - Biodesix
 
Jeffrey Allen Borgia
No Relationships to Disclose
 
Philip D. Bonomi
Honoraria - AstraZeneca; Biodesix; Bristol-Myers Squibb; Helsinn Therapeutics; Lilly; Merck; pfizer; Roche/Genentech; Trovagene
Consulting or Advisory Role - AstraZeneca; Biodesix; Bristol-Myers Squibb; Helsinn Therapeutics; Lilly; Merck; Merck; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Biodesix (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Marta Batus
No Relationships to Disclose